cagrisema vs semaglutide Three new phase 3 REIMAGINE studies provide some of the strongest evidence yet for CagriSema® (cagrilintide + semaglutide) in type 2 diabetes. 🔹 REIMAGINE 1 Studied people with early type 2 diabetes Novo Nordisk launches trial of

There was no change in fasting plasma glucose for either group, the researchers reported

Further enhancement of the reducing condition might be an alternative approach for the selective toxicity to NRF2-addicted cancer cells by provoking the reductive stress

Wang L, Berger NA, Kaelber DC, Xu R

doi: 10.1186/s12958-024-01252-4

Hypoglycaemia risk is generally low with Mounjaro monotherapy, as its glucose-lowering effect is glucose-dependent

And familiarity with the side-effect profiles of bisphosphonates, particularly atypical femoral fractures and osteonecrosis of the jaw, makes us better partners in the management of our patients' bone health